Clinical Trial

A Study of HS-20122 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of HS-20122, in patients with advanced solid tumors. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-20122 in advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-14.
Status change: Not Yet Recruiting → Recruiting 2026-01-15
Trial Details
NCT Number NCT06927570
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Advanced Solid Tumors
Enrollment 1,050 participants
Start Date 2025-04-15
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-16